Cite
HARVARD Citation
Shan, J. et al. (n.d.). 137P Tislelizumab combined with chemotherapy as neoadjuvant therapy for stage IIIA-IIIB(N2) potentially resectable squamous non-small-cell lung cancer (TACT). Immuno-oncology technology. p. . [Online].